{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:03:43Z","timestamp":1793239423935,"version":"4.5.0"},"reference-count":261,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>The frequent co-occurrence of major depressive disorder (MDD) and substance use disorders\n(SUDs) entails significant clinical challenges. Compared to patients with MDD alone, patients\nwith MDD and SUD often show increased anhedonia, emotional blunting, and impaired cognitive\nfunction. These symptoms lead to an inability to control cravings, more substance use, increased relapse\nrates, and poor adherence to the treatment. This fosters a detrimental cycle leading to more severe\ndepressive symptoms, functional impairment, and chronicity, culminating in heightened morbidity,\nmortality, and healthcare resource utilization. Data on antidepressant treatment of MDD-SUD patients\nare inconclusive and often conflicting because of a number of confounding factors in clinical trials\nor difficulty in dissecting the specific contributions of pharmacological versus psychological interventions\nin real-world studies. The patient's unique clinical features and specific SUD and MDD subtypes\nmust be considered when choosing treatments. Ideally, drug treatment for MDD-SUD should act\non both conditions and address core symptoms such as anhedonia, craving, and cognitive dysfunction\nwhile ensuring minimal emotional blunting, absence of drug interactions, and no addictive potential.\nThis approach aims to address unmet needs and optimize the outcomes in a clinical population often\nunderrepresented in treatment paradigms.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x22666240827165327","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T07:47:30Z","timestamp":1725263250000},"page":"256-275","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Major Depression in Comorbidity with Substance use Disorders: Patients\u2019 Features and Clinical-Neurobiological Rationale of Antidepressant Treatments"],"prefix":"10.2174","volume":"23","author":[{"given":"Sergio","family":"De Filippis","sequence":"first","affiliation":[{"name":"Villa Von Siebenthal Clinic, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinotti","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Imaging, and Clinical Sciences, University\nG. D\u2019Annunzio, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Nicoletti","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Sapienza University, Rome, Italy"},{"name":"Department of Molecular Pathology, IRCCS Neuromed, Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mastrostefano","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Trovini","sequence":"additional","affiliation":[{"name":"Villa Von Siebenthal Clinic, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pugliese","sequence":"additional","affiliation":[{"name":"Medical Department, Lundbeck Italia, Milan,\nItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Di Nicola","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy"},{"name":"Department of Neuroscience, Section of Psychiatry, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/wps.20802","volume":"19","author":"Plana-Ripoll O.","year":"2020","unstructured":"Plana-Ripoll O.; Musliner K.L.; Dalsgaard S.; Momen N.C.; Weye N.; Christensen M.K.; Agerbo E.; Iburg K.M.; Laursen T.M.; Mortensen P.B.; Pedersen C.B.; Petersen L.V.; Santomauro D.F.; Vilhj\u00e1lmsson B.J.; Whiteford H.A.; McGrath J.J.; Nature and prevalence of combinations of mental disorders and their association with excess mortality in a population-based cohort study. World Psychiatry  2020,19(3),339-349","journal-title":"World Psychiatry"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jad.2016.07.011","volume":"206","author":"Hunt G.E.","year":"2016","unstructured":"Hunt G.E.; Malhi G.S.; Cleary M.; Lai H.M.X.; Sitharthan T.; Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990-2015: Systematic review and meta-analysis. J Affect Disord  2016,206,331-349","journal-title":"J Affect Disord"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","volume":"191","author":"Hunt G.E.","year":"2018","unstructured":"Hunt G.E.; Large M.M.; Cleary M.; Lai H.M.X.; Saunders J.B.; Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis. Drug Alcohol Depend  2018,191,234-258","journal-title":"Drug Alcohol Depend"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1017\/S1092852920001479","volume":"26","author":"Martinotti G.","year":"2021","unstructured":"Martinotti G.; De Risio L.; Vannini C.; Schifano F.; Pettorruso M.; Di Giannantonio M.; Substance-related exogenous psychosis: a postmodern syndrome. CNS Spectr  2021,26(1),84-91","journal-title":"CNS Spectr"},{"key":"ref=5","year":"2017","unstructured":"World Health Organization Depression and Other Common Mental Disorders: Global Health Estimates  Available from:  https:\/\/www.who.int\/publications\/i\/item\/depression-global-health-estimates2017","journal-title":"Depression and Other Common Mental Disorders: Global Health Estimates"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jad.2020.01.141","volume":"266","author":"Hunt G.E.","year":"2020","unstructured":"Hunt G.E.; Malhi G.S.; Lai H.M.X.; Cleary M.; Prevalence of comorbid substance use in major depressive disorder in community and clinical settings, 1990-2019: Systematic review and meta-analysis. J Affect Disord  2020,266,288-304","journal-title":"J Affect Disord"},{"key":"ref=7","year":"2017","unstructured":"American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder  Available from:   https:\/\/psychiatryonline.org\/doi\/book\/10.1176\/appi.books.97816153719692017"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"865","DOI":"10.4088\/JCP.10m06673","volume":"73","author":"Blanco C.","year":"2012","unstructured":"Blanco C.; Alegr\u00eda A.A.; Liu S.M.; Secades-Villa R.; Sugaya L.; Davies C.; Nunes E.V.; Differences among major depressive disorder with and without co-occurring substance use disorders and substance-induced depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry  2012,73(6),865-873","journal-title":"J Clin Psychiatry"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/0376-8716(91)90010-V","volume":"27","author":"Hasegawa K.","year":"1991","unstructured":"Hasegawa K.; Mukasa H.; Nakazawa Y.; Kodama H.; Nakamura K.; Miura Y.; Sato T.; Primary and secondary depression in alcoholism - clinical features and family history. Drug Alcohol Depend  1991,27(3),275-281","journal-title":"Drug Alcohol Depend"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1192\/bjp.143.2.133","volume":"143","author":"O\u2019Sullivan K.","year":"1983","unstructured":"O\u2019Sullivan K.; Whillans P.; Daly M.; Carroll B.; Clare A.; Cooney J.; A comparison of alcoholics with and without coexisting affective disorder. Br J Psychiatry  1983,143(2),133-138","journal-title":"Br J Psychiatry"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.15288\/jsa.2002.63.363","volume":"63","author":"Kahler C.W.","year":"2002","unstructured":"Kahler C.W.; Ramsey S.E.; Read J.P.; Brown R.A.; McCrady B.S.; Brown R.A.; Substance-induced and independent major depressive disorder in treatment-seeking alcoholics: associations with dysfunctional attitudes and coping. J Stud Alcohol  2002,63(3),363-371","journal-title":"J Stud Alcohol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.4088\/JCP.v67n1010","volume":"67","author":"Nunes E.V.","year":"2006","unstructured":"Nunes E.V.; Liu X.; Samet S.; Matseoane K.; Hasin D.; Independent versus substance-induced major depressive disorder in substance-dependent patients: observational study of course during follow-up. J Clin Psychiatry  2006,67(10),1561-1567","journal-title":"J Clin Psychiatry"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"672","DOI":"10.15288\/jsa.2004.65.672","volume":"65","author":"Ramsey S.E.","year":"2004","unstructured":"Ramsey S.E.; Kahler C.W.; Read J.P.; Stuart G.L.; Brown R.A.; Discriminating between substance-induced and independent depressive episodes in alcohol dependent patients. J Stud Alcohol  2004,65(5),672-676","journal-title":"J Stud Alcohol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/YCO.0b013e3282f32408","volume":"21","author":"Davis L.","year":"2008","unstructured":"Davis L.; Uezato A.; Newell J.M.; Frazier E.; Major depression and comorbid substance use disorders. Curr Opin Psychiatry  2008,21(1),14-18","journal-title":"Curr Opin Psychiatry"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.amjmed.2005.01.007","volume":"118","author":"Sullivan L.E.","year":"2005","unstructured":"Sullivan L.E.; Fiellin D.A.; O\u2019Connor P.G.; The prevalence and impact of alcohol problems in major depression: A systematic review. Am J Med  2005,118(4),330-341","journal-title":"Am J Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/wps.21073","volume":"22","author":"Volkow N.D.","year":"2023","unstructured":"Volkow N.D.; Blanco C.; Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention. World Psychiatry  2023,22(2),203-229","journal-title":"World Psychiatry"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1017\/S109285292000173X","volume":"27","author":"Di Nicola M.","year":"2022","unstructured":"Di Nicola M.; Pepe M.; Panaccione I.; Moccia L.; Dattoli L.; Molinaro M.; Sani G.; Janiri L.; McIntyre R.S.; Fiorillo A.; Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis. CNS Spectr  2022,27(1),73-81","journal-title":"CNS Spectr"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.2174\/1570159X21666230403080624","volume":"21","author":"Di Nicola M.","year":"2023","unstructured":"Di Nicola M.; Pepe M.; Panaccione I.; Moccia L.; Janiri L.; Sani G.; Update on pharmacological treatment for comorbid major depressive and alcohol use disorders: The role of extended-release trazodone. Curr Neuropharmacol  2023,21(11),2195-2205","journal-title":"Curr Neuropharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/cns.13437","volume":"26","author":"Li J.","year":"2020","unstructured":"Li J.; Wang H.; Li M.; Shen Q.; Li X.; Rong X.; Peng Y.; Efficacy of pharmacotherapeutics for patients comorbid with alcohol use disorders and depressive symptoms-A bayesian network meta-analysis. CNS Neurosci Ther  2020,26(11),1185-1197","journal-title":"CNS Neurosci Ther"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.2174\/1570159X19666210113150123","volume":"19","author":"Kotzalidis G.D.","year":"2021","unstructured":"Kotzalidis G.D.; Lombardozzi G.; Matrone M.; Amici E.; Perrini F.; Cuomo I.; De Filippis S.; Vortioxetine vs. Other antidepressants in patients with major depressive episode with or without substance use disorder. Curr Neuropharmacol  2021,19(12),2296-2307","journal-title":"Curr Neuropharmacol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1176\/appi.ajp.2012.12010112","volume":"170","author":"Pettinati H.M.","year":"2013","unstructured":"Pettinati H.M.; O\u2019Brien C.P.; Dundon W.D.; Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry  2013,170(1),23-30","journal-title":"Am J Psychiatry"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1176\/appi.ajp.2009.08060852","volume":"167","author":"Pettinati H.M.","year":"2010","unstructured":"Pettinati H.M.; Oslin D.W.; Kampman K.M.; Dundon W.D.; Xie H.; Gallis T.L.; Dackis C.A.; O\u2019Brien C.P.; A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry  2010,167(6),668-675","journal-title":"Am J Psychiatry"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jad.2015.06.024","volume":"185","author":"Foulds J.A.","year":"2015","unstructured":"Foulds J.A.; Adamson S.J.; Boden J.M.; Williman J.A.; Mulder R.T.; Depression in patients with alcohol use disorders: Systematic review and meta-analysis of outcomes for independent and substance-induced disorders. J Affect Disord  2015,185,47-59","journal-title":"J Affect Disord"},{"key":"ref=24","year":"2018","unstructured":"World Health Organization (WHO)  Global status report on alcohol and health 2018  2018","journal-title":"Global status report on alcohol and health 2018"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.20882\/adicciones.933","volume":"29","author":"Torrens M.","year":"2017","unstructured":"Torrens M.; Mestre-Pint\u00f3 J.I.; Montanari L.; Vicente J.; Domingo-Salvany A.; Dual diagnosis: an European perspective. Adicciones  2017,29(1),3-5","journal-title":"Adicciones"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"106128","DOI":"10.1016\/j.addbeh.2019.106128","volume":"102","author":"Glantz M.D.","year":"2020","unstructured":"Glantz M.D.; Bharat C.; Degenhardt L.; Sampson N.A.; Scott K.M.; Lim C.C.W.; Al-Hamzawi A.; Alonso J.; Andrade L.H.; Cardoso G.; De Girolamo G.; Gureje O.; He Y.; Hinkov H.; Karam E.G.; Karam G.; Kovess-Masfety V.; Lasebikan V.; Lee S.; Levinson D.; McGrath J.; Medina-Mora M.E.; Mihaescu-Pintia C.; Mneimneh Z.; Moskalewicz J.; Navarro-Mateu F.; Posada-Villa J.; Rapsey C.; Stagnaro J.C.; Tachimori H.; Ten Have M.; Tintle N.; Torres Y.; Williams D.R.; Ziv Y.; Kessler R.C.; The epidemiology of alcohol use disorders cross-nationally: Findings from the World Mental Health Surveys. Addict Behav  2020,102,106128","journal-title":"Addict Behav"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.05.031","volume":"154","author":"Lai H.M.X.","year":"2015","unstructured":"Lai H.M.X.; Cleary M.; Sitharthan T.; Hunt G.E.; Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990-2014: A systematic review and meta-analysis. Drug Alcohol Depend  2015,154,1-13","journal-title":"Drug Alcohol Depend"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"eaau1184","DOI":"10.1126\/science.aau1184","volume":"361","author":"Jalal H.","year":"2018","unstructured":"Jalal H.; Buchanich J.M.; Roberts M.S.; Balmert L.C.; Zhang K.; Burke D.S.; Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science  2018,361(6408),eaau1184","journal-title":"Science"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1111\/add.14724","volume":"114","author":"McDonald A.J.","year":"2019","unstructured":"McDonald A.J.; Roerecke M.; Mann R.E.; Adolescent cannabis use and risk of mental health problems-the need for newer data. Addiction  2019,114(10),1889-1890","journal-title":"Addiction"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","volume":"26","author":"Volkow N.D.","year":"2021","unstructured":"Volkow N.D.; Blanco C.; The changing opioid crisis: development, challenges and opportunities. Mol Psychiatry  2021,26(1),218-233","journal-title":"Mol Psychiatry"},{"key":"ref=31","year":"2021","unstructured":"United Nations Office on Drugs and Crime, World drug report - drug market trends: Cannabis and opioids  Available from:  https:\/\/www.unodc.org\/unodc\/data-and-analysis\/wdr2021.html2021","journal-title":"World drug report - drug market trends: Cannabis and opioids"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"109551","DOI":"10.1016\/j.drugalcdep.2022.109551","volume":"238","author":"Santo T.","year":"2022","unstructured":"Santo T.; Campbell G.; Gisev N.; Martino-Burke D.; Wilson J.; Colledge-Frisby S.; Clark B.; Tran L.T.; Degenhardt L.; Prevalence of mental disorders among people with opioid use disorder: A systematic review and meta-analysis. Drug Alcohol Depend  2022,238,109551","journal-title":"Drug Alcohol Depend"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1111\/add.14234","volume":"113","author":"Peacock A.","year":"2018","unstructured":"Peacock A.; Leung J.; Larney S.; Colledge S.; Hickman M.; Rehm J.; Giovino G.A.; West R.; Hall W.; Griffiths P.; Ali R.; Gowing L.; Marsden J.; Ferrari A.J.; Grebely J.; Farrell M.; Degenhardt L.; Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction  2018,113(10),1905-1926","journal-title":"Addiction"},{"key":"ref=34","first-page":"531","volume":"40","author":"Ravelli A.","year":"1998","unstructured":"Ravelli A.; Bijl R.V.; van Zessen G.; Comorbidity of psychiatric disorders in the Dutch population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Tijdschr Psychiatr  1998,40,531-544","journal-title":"Tijdschr Psychiatr"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/jamapsychiatry.2018.4500","volume":"76","author":"Gobbi G.","year":"2019","unstructured":"Gobbi G.; Atkin T.; Zytynski T.; Wang S.; Askari S.; Boruff J.; Ware M.; Marmorstein N.; Cipriani A.; Dendukuri N.; Mayo N.; Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood. JAMA Psychiatry  2019,76(4),426-434","journal-title":"JAMA Psychiatry"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"625158","DOI":"10.3389\/fpsyt.2021.625158","volume":"12","author":"Langlois C.","year":"2021","unstructured":"Langlois C.; Potvin S.; Khullar A.; Tourjman S.V.; Down and high: Reflections regarding depression and cannabis. Front Psychiatry  2021,12,625158","journal-title":"Front Psychiatry"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.neuropharm.2014.01.006","volume":"87","author":"Gon\u00e7alves J.","year":"2014","unstructured":"Gon\u00e7alves J.; Baptista S.; Silva A.P.; Psychostimulants and brain dysfunction: A review of the relevant neurotoxic effects. Neuropharmacology  2014,87,135-149","journal-title":"Neuropharmacology"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.pnpbp.2003.11.018","volume":"28","author":"Elhwuegi A.S.","year":"2004","unstructured":"Elhwuegi A.S.; Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry  2004,28(3),435-451","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.drugalcdep.2008.05.005","volume":"98","author":"Conner K.R.","year":"2008","unstructured":"Conner K.R.; Pinquart M.; Holbrook A.P.; Meta-analysis of depression and substance use and impairment among cocaine users. Drug Alcohol Depend  2008,98(1-2),13-23","journal-title":"Drug Alcohol Depend"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1465-3362.2009.00081.x","volume":"29","author":"Glasner-Edwards S.","year":"2010","unstructured":"Glasner-Edwards S.; Mooney L.J.; Marinelli-Casey P.; Hillhouse M.; Ang A.; Rawson R.A.; Psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug Alcohol Rev  2010,29(1),12-20","journal-title":"Drug Alcohol Rev"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/JAN.0000000000000058","volume":"26","author":"Hellem T.L.","year":"2015","unstructured":"Hellem T.L.; Lundberg K.J.; Renshaw P.F.; A review of treatment options for co-occurring methamphetamine use disorders and depression. J Addict Nurs  2015,26(1),14-23","journal-title":"J Addict Nurs"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.biopsych.2004.05.009","volume":"56","author":"Rounsaville B.J.","year":"2004","unstructured":"Rounsaville B.J.; Treatment of cocaine dependence and depression. Biol Psychiatry  2004,56(10),803-809","journal-title":"Biol Psychiatry"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0376-8716(95)01160-4","volume":"39","author":"Grant B.F.","year":"1995","unstructured":"Grant B.F.; Harford T.C.; Comorbidity between DSM-IV alcohol use disorders and major depression: results of a national survey. Drug Alcohol Depend  1995,39(3),197-206","journal-title":"Drug Alcohol Depend"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/archpsyc.62.10.1097","volume":"62","author":"Hasin D.S.","year":"2005","unstructured":"Hasin D.S.; Goodwin R.D.; Stinson F.S.; Grant B.F.; Epidemiology of major depressive disorder. Arch Gen Psychiatry  2005,62(10),1097-1106","journal-title":"Arch Gen Psychiatry"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1360-0443.2010.03351.x","volume":"106","author":"Boden J.M.","year":"2011","unstructured":"Boden J.M.; Fergusson D.M.; Alcohol and depression. Addiction  2011,106(5),906-914","journal-title":"Addiction"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"572245","DOI":"10.3389\/fpsyt.2020.572245","volume":"11","author":"Martinotti G.","year":"2020","unstructured":"Martinotti G.; Alessi M.C.; Di Natale C.; Sociali A.; Ceci F.; Lucidi L.; Picutti E.; Di Carlo F.; Corbo M.; Vellante F.; Fiori F.; Tourjansky G.; Catalano G.; Carenti M.L.; Incerti C.C.; Bartoletti L.; Barlati S.; Romeo V.M.; Verrastro V.; De Giorgio F.; Valchera A.; Sepede G.; Casella P.; Pettorruso M.; di Giannantonio M.; Psychopathological burden and quality of life in substance users during the COVID-19 lockdown period in Italy. Front Psychiatry  2020,11,572245","journal-title":"Front Psychiatry"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0140-6736(09)60009-X","volume":"373","author":"Schuckit M.A.","year":"2009","unstructured":"Schuckit M.A.; Alcohol-use disorders. Lancet  2009,373(9662),492-501","journal-title":"Lancet"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.psc.2019.10.012","volume":"43","author":"Di Nicola M.","year":"2020","unstructured":"Di Nicola M.; Pepe M.; Modica M.; Lanzotti P.; Panaccione I.; Moccia L.; Janiri L.; Mixed states in patients with substance and behavioral addictions. Psychiatr Clin North Am  2020,43(1),127-137","journal-title":"Psychiatr Clin North Am"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1176\/ajp.156.9.1444","volume":"156","author":"Uslaner J.","year":"1999","unstructured":"Uslaner J.; Kalechstein A.; Richter T.; Ling W.; Newton T.; Association of depressive symptoms during abstinence with the subjective high produced by cocaine. Am J Psychiatry  1999,156(9),1444-1446","journal-title":"Am J Psychiatry"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1046\/j.1360-0443.2003.00437.x","volume":"98","author":"Degenhardt L.","year":"2003","unstructured":"Degenhardt L.; Hall W.; Lynskey M.; Exploring the association between cannabis use and depression. Addiction  2003,98(11),1493-1504","journal-title":"Addiction"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1017\/S0033291713001438","volume":"44","author":"Lev-Ran S.","year":"2014","unstructured":"Lev-Ran S.; Roerecke M.; Le Foll B.; George T.P.; McKenzie K.; Rehm J.; The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med  2014,44(4),797-810","journal-title":"Psychol Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1001\/jamapsychiatry.2023.1256","volume":"80","author":"Jefsen O.H.","year":"2023","unstructured":"Jefsen O.H.; Erlangsen A.; Nordentoft M.; Hjorth\u00f8j C.; Cannabis use disorder and subsequent risk of psychotic and nonpsychotic unipolar depression and bipolar disorder. JAMA Psychiatry  2023,80(8),803-810","journal-title":"JAMA Psychiatry"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"e2113025","DOI":"10.1001\/jamanetworkopen.2021.13025","volume":"4","author":"Han B.","year":"2021","unstructured":"Han B.; Compton W.M.; Einstein E.B.; Volkow N.D.; Associations of suicidality trends with cannabis use as a function of sex and depression status. JAMA Netw Open  2021,4(6),e2113025","journal-title":"JAMA Netw Open"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.chc.2016.03.002","volume":"25","author":"Sharma B.","year":"2016","unstructured":"Sharma B.; Bruner A.; Barnett G.; Fishman M.; Opioid use disorders. Child Adolesc Psychiatr Clin N Am  2016,25(3),473-487","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3390\/ijerph16030447","volume":"16","author":"Maremmani A.G.I.","year":"2019","unstructured":"Maremmani A.G.I.; Pacini M.; Maremmani I.; What we have learned from the methadone maintenance treatment of dual disorder heroin use disorder patients. Int J Environ Res Public Health  2019,16(3),447","journal-title":"Int J Environ Res Public Health"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/add.12860","volume":"110","author":"Teesson M.","year":"2015","unstructured":"Teesson M.; Marel C.; Darke S.; Ross J.; Slade T.; Burns L.; Lynskey M.; Memedovic S.; White J.; Mills K.L.; Long-term mortality, remission, criminality and psychiatric comorbidity of heroin dependence: 11-year findings from the Australian Treatment Outcome Study. Addiction  2015,110(6),986-993","journal-title":"Addiction"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jsat.2017.03.006","volume":"77","author":"Hser Y.I.","year":"2017","unstructured":"Hser Y.I.; Mooney L.J.; Saxon A.J.; Miotto K.; Bell D.S.; Huang D.; Chronic pain among patients with opioid use disorder: Results from electronic health records data. J Subst Abuse Treat  2017,77,26-30","journal-title":"J Subst Abuse Treat"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12954-020-00396-x","volume":"17","author":"Morin K.A.","year":"2020","unstructured":"Morin K.A.; Eibl J.K.; Gauthier G.; Rush B.; Mushquash C.; Lightfoot N.E.; Marsh D.C.; A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data. Harm Reduct J  2020,17(1),51","journal-title":"Harm Reduct J"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","volume":"9","author":"Kampman K.","year":"2015","unstructured":"Kampman K.; Jarvis M.; American society of addiction medicine (asam) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med  2015,9(5),358-367","journal-title":"J Addict Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"100195","DOI":"10.1016\/j.dadr.2023.100195","volume":"9","author":"Xu K.Y.","year":"2023","unstructured":"Xu K.Y.; Huang V.; Williams A.R.; Martin C.E.; Bazazi A.R.; Grucza R.A.; Co-occurring psychiatric disorders and disparities in buprenorphine utilization in opioid use disorder: An analysis of insurance claims. Drug Alcohol Depend Rep  2023,9,100195","journal-title":"Drug Alcohol Depend Rep"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"108651","DOI":"10.1016\/j.drugalcdep.2021.108651","volume":"221","author":"Hall N.Y.","year":"2021","unstructured":"Hall N.Y.; Le L.; Majmudar I.; Mihalopoulos C.; Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective. Drug Alcohol Depend  2021,221,108651","journal-title":"Drug Alcohol Depend"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jsat.2013.07.012","volume":"46","author":"Mojtabai R.","year":"2014","unstructured":"Mojtabai R.; Chen L.Y.; Kaufmann C.N.; Crum R.M.; Comparing barriers to mental health treatment and substance use disorder treatment among individuals with comorbid major depression and substance use disorders. J Subst Abuse Treat  2014,46(2),268-273","journal-title":"J Subst Abuse Treat"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","volume":"394","author":"Degenhardt L.","year":"2019","unstructured":"Degenhardt L.; Grebely J.; Stone J.; Hickman M.; Vickerman P.; Marshall B.D.L.; Bruneau J.; Altice F.L.; Henderson G.; Rahimi-Movaghar A.; Larney S.; Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet  2019,394(10208),1560-1579","journal-title":"Lancet"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1093\/aje\/kwp186","volume":"170","author":"Nosyk B.","year":"2009","unstructured":"Nosyk B.; MacNab Y.C.; Sun H.; Fischer B.; Marsh D.C.; Schechter M.T.; Anis A.H.; Proportional hazards frailty models for recurrent methadone maintenance treatment. Am J Epidemiol  2009,170(6),783-792","journal-title":"Am J Epidemiol"},{"key":"ref=65","first-page":"126","volume":"43","author":"Gelkopf M.","year":"2006","unstructured":"Gelkopf M.; Weizman T.; Melamed Y.; Adelson M.; Bleich A.; Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic. Isr J Psychiatry Relat Sci  2006,43(2),126-136","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.3390\/ijerph6112822","volume":"6","author":"Astals M.","year":"2009","unstructured":"Astals M.; D\u00edaz L.; Domingo-Salvany A.; Mart\u00edn-Santos R.; Bulbena A.; Torrens M.; Impact of co-occurring psychiatric disorders on retention in a methadone maintenance program: an 18-month follow-up study. Int J Environ Res Public Health  2009,6(11),2822-2832","journal-title":"Int J Environ Res Public Health"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"108244","DOI":"10.1016\/j.drugalcdep.2020.108244","volume":"216","author":"Friesen E.L.","year":"2020","unstructured":"Friesen E.L.; Kurdyak P.; The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder. Drug Alcohol Depend  2020,216,108244","journal-title":"Drug Alcohol Depend"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/add.15625","volume":"117","author":"Virtanen S.","year":"2022","unstructured":"Virtanen S.; Lagerberg T.; Khemiri L.; Suvisaari J.; Larsson H.; Lichtenstein P.; Chang Z.; Latvala A.; Association of selective serotonin re-uptake inhibitor (SSRI) treatment with acute substance misuse outcomes. Addiction  2022,117(1),234-242","journal-title":"Addiction"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/add.14866","volume":"115","author":"Brenner P.","year":"2020","unstructured":"Brenner P.; Brandt L.; Li G.; DiBernardo A.; Bod\u00e9n R.; Reutfors J.; Substance use disorders and risk for treatment resistant depression: a population-based, nested case-control study. Addiction  2020,115(4),768-777","journal-title":"Addiction"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1176\/appi.ajp.2020.20040454","volume":"178","author":"Coughlin L.N.","year":"2021","unstructured":"Coughlin L.N.; Pfeiffer P.; Ganoczy D.; Lin L.A.; Quality of outpatient depression treatment in patients with comorbid substance use disorder. Am J Psychiatry  2021,178(5),414-423","journal-title":"Am J Psychiatry"},{"key":"ref=71","first-page":"858","volume":"82","author":"Kohn R.","year":"2004","unstructured":"Kohn R.; Saxena S.; Levav I.; Saraceno B.; The treatment gap in mental health care. Bull World Health Organ  2004,82(11),858-866","journal-title":"Bull World Health Organ"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.addbeh.2010.12.021","volume":"36","author":"Merkx M.J.M.","year":"2011","unstructured":"Merkx M.J.M.; Schippers G.M.; Koeter M.W.J.; Vuijk P.J.; Oudejans S.C.C.; Stam R.K.; van den Brink W.; Guidelines for allocating outpatient alcohol abusers to levels of care: Predictive validity. Addict Behav  2011,36(6),570-575","journal-title":"Addict Behav"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/dar.13568","volume":"42","author":"Pepe M.","year":"2023","unstructured":"Pepe M.; Di Nicola M.; Panaccione I.; Franza R.; De Berardis D.; Cibin M.; Janiri L.; Sani G.; Impulsivity and alexithymia predict early versus subsequent relapse in patients with alcohol use disorder: A 1-year longitudinal study. Drug Alcohol Rev  2023,42(2),367-372","journal-title":"Drug Alcohol Rev"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jpsychires.2017.02.026","volume":"91","author":"Han B.","year":"2017","unstructured":"Han B.; Olfson M.; Mojtabai R.; Depression care among adults with co-occurring major depressive episodes and substance use disorders in the United States. J Psychiatr Res  2017,91,47-56","journal-title":"J Psychiatr Res"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1097\/MLR.0000000000000036","volume":"52","author":"Jordan N.","year":"2014","unstructured":"Jordan N.; Sohn M.W.; Bartle B.; Valenstein M.; Lee Y.; Lee T.A.; Pfeiffer P.N.; Kim H.M.; Valenstein M.; Association between chronic illness complexity and receipt of evidence-based depression care. Med Care  2014,52(Suppl. 2),S126-S131","journal-title":"Med Care"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.291.15.1887","volume":"291","author":"Nunes E.V.","year":"2004","unstructured":"Nunes E.V.; Levin F.R.; Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA  2004,291(15),1887-1896","journal-title":"JAMA"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.drugalcdep.2009.10.003","volume":"107","author":"Davis L.L.","year":"2010","unstructured":"Davis L.L.; Wisniewski S.R.; Howland R.H.; Trivedi M.H.; Husain M.M.; Fava M.; McGrath P.J.; Balasubramani G.K.; Warden D.; Rush A.J.; Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug Alcohol Depend  2010,107(2-3),161-170","journal-title":"Drug Alcohol Depend"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-244X-9-6","volume":"9","author":"Hesse M.","year":"2009","unstructured":"Hesse M.; Integrated psychological treatment for substance use and co-morbid anxiety or depression vs. treatment for substance use alone. A systematic review of the published literature. BMC Psychiatry  2009,9(1),6","journal-title":"BMC Psychiatry"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"392","DOI":"10.4088\/JCP.v69n0308","volume":"69","author":"Muhonen L.H.","year":"2008","unstructured":"Muhonen L.H.; L\u00f6nnqvist J.; Juva K.; Alho H.; Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry  2008,69(3),392-399","journal-title":"J Clin Psychiatry"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/13811110903263191","volume":"13","author":"Schneider B.","year":"2009","unstructured":"Schneider B.; Substance use disorders and risk for completed suicide. Arch Suicide Res  2009,13(4),303-316","journal-title":"Arch Suicide Res"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.35946\/arcr.v40.1.01","volume":"40","author":"McHugh R.K.","year":"2019","unstructured":"McHugh R.K.; Weiss R.D.; Alcohol use disorder and depressive disorders. Alcohol Res  2019,40(1),1-01","journal-title":"Alcohol Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"907","DOI":"10.4088\/JCP.v69n0604","volume":"69","author":"Sher L.","year":"2008","unstructured":"Sher L.; Stanley B.H.; Harkavy-Friedman J.M.; Carballo J.J.; Arendt M.; Brent D.A.; Sperling D.; Lizardi D.; Mann J.J.; Oquendo M.A.; Depressed patients with co-occurring alcohol use disorders: a unique patient population. J Clin Psychiatry  2008,69(6),907-915","journal-title":"J Clin Psychiatry"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.drugalcdep.2018.02.009","volume":"187","author":"Carton L.","year":"2018","unstructured":"Carton L.; Pignon B.; Baguet A.; Benradia I.; Roelandt J.L.; Vaiva G.; Thomas P.; Amad A.; De Timary P.; Naassila M.; Geoffroy P.A.; Rolland B.; Influence of comorbid alcohol use disorders on the clinical patterns of major depressive disorder: A general population-based study. Drug Alcohol Depend  2018,187,40-47","journal-title":"Drug Alcohol Depend"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"108535","DOI":"10.1016\/j.drugalcdep.2021.108535","volume":"220","author":"Abdellaoui A.","year":"2021","unstructured":"Abdellaoui A.; Smit D.J.A.; van den Brink W.; Denys D.; Verweij K.J.H.; Genomic relationships across psychiatric disorders including substance use disorders. Drug Alcohol Depend  2021,220,108535","journal-title":"Drug Alcohol Depend"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/jamapsychiatry.2017.2269","volume":"74","author":"Andersen A.M.","year":"2017","unstructured":"Andersen A.M.; Pietrzak R.H.; Kranzler H.R.; Ma L.; Zhou H.; Liu X.; Kramer J.; Kuperman S.; Edenberg H.J.; Nurnberger J.I.; Rice J.P.; Tischfield J.A.; Goate A.; Foroud T.M.; Meyers J.L.; Porjesz B.; Dick D.M.; Hesselbrock V.; Boerwinkle E.; Southwick S.M.; Krystal J.H.; Weissman M.M.; Levinson D.F.; Potash J.B.; Gelernter J.; Han S.; Polygenic scores for major depressive disorder and risk of alcohol dependence. JAMA Psychiatry  2017,74(11),1153-1160","journal-title":"JAMA Psychiatry"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.drugalcdep.2018.02.027","volume":"189","author":"Crum R.M.","year":"2018","unstructured":"Crum R.M.; Green K.M.; Stuart E.A.; La Flair L.N.; Kealhofer M.; Young A.S.; Krawczyk N.; Tormohlen K.N.; Storr C.L.; Alvanzo A.A.H.; Mojtabai R.; Pacek L.R.; Cullen B.A.; Reboussin B.A.; Transitions through stages of alcohol involvement: The potential role of mood disorders. Drug Alcohol Depend  2018,189,116-124","journal-title":"Drug Alcohol Depend"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.psychres.2018.10.013","volume":"270","author":"Pavkovic B.","year":"2018","unstructured":"Pavkovic B.; Zaric M.; Markovic M.; Klacar M.; Huljic A.; Caricic A.; Double screening for dual disorder, alcoholism and depression. Psychiatry Res  2018,270,483-489","journal-title":"Psychiatry Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1017\/S0033291711001681","volume":"42","author":"Boschloo L.","year":"2012","unstructured":"Boschloo L.; van den Brink W.; Penninx B.W.J.H.; Wall M.M.; Hasin D.S.; Alcohol-use disorder severity predicts first-incidence of depressive disorders. Psychol Med  2012,42(4),695-703","journal-title":"Psychol Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1176\/appi.ajp.158.3.399","volume":"158","author":"Brower K.J.","year":"2001","unstructured":"Brower K.J.; Aldrich M.S.; Robinson E.A.R.; Zucker R.A.; Greden J.F.; Insomnia, self-medication, and relapse to alcoholism. Am J Psychiatry  2001,158(3),399-404","journal-title":"Am J Psychiatry"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1111\/j.1530-0277.2006.00245.x","volume":"30","author":"Conroy D.A.","year":"2006","unstructured":"Conroy D.A.; Todd Arnedt J.; Brower K.J.; Strobbe S.; Consens F.; Hoffmann R.; Armitage R.; Hoffmann R.F.; Armitage R.; Perception of sleep in recovering alcohol-dependent patients with insomnia: relationship with future drinking. Alcohol Clin Exp Res  2006,30(12),1992-1999","journal-title":"Alcohol Clin Exp Res"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/j.1530-0277.1999.tb04223.x","volume":"23","author":"Foster J.H.","year":"1999","unstructured":"Foster J.H.; Peters T.J.; Impaired sleep in alcohol misusers and dependent alcoholics and the impact upon outcome. Alcohol Clin Exp Res  1999,23(6),1044-1051","journal-title":"Alcohol Clin Exp Res"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.addbeh.2013.09.022","volume":"39","author":"Chakravorty S.","year":"2014","unstructured":"Chakravorty S.; Grandner M.A.; Mavandadi S.; Perlis M.L.; Sturgis E.B.; Oslin D.W.; Rahman M.; Appleby D.; Atwood C.W.; Carskadon M.A.; Dinges D.F.; Suicidal ideation in Veterans misusing alcohol: Relationships with insomnia symptoms and sleep duration. Addict Behav  2014,39(2),399-405","journal-title":"Addict Behav"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jad.2011.01.011","volume":"135","author":"Baglioni C.","year":"2011","unstructured":"Baglioni C.; Battagliese G.; Feige B.; Spiegelhalder K.; Nissen C.; Voderholzer U.; Lombardo C.; Riemann D.; Insomnia as a predictor of depression: A meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord  2011,135(1-3),10-19","journal-title":"J Affect Disord"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3109\/10826084.2013.781182","volume":"48","author":"Zhabenko O.","year":"2013","unstructured":"Zhabenko O.; Krentzman A.R.; Robinson E.A.R.; Brower K.J.; Zucker R.A.; A longitudinal study of drinking and depression as predictors of insomnia in alcohol-dependent individuals. Subst Use Misuse  2013,48(7),495-505","journal-title":"Subst Use Misuse"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1521-0391.2013.12056.x","volume":"23","author":"Kolla B.P.","year":"2014","unstructured":"Kolla B.P.; Schneekloth T.; Biernacka J.; Mansukhani M.; Geske J.; Karpyak V.; Hall-Flavin D.; Louikianova L.; Frye M.A.; The course of sleep disturbances in early alcohol recovery: an observational cohort study. Am J Addict  2014,23(1),21-26","journal-title":"Am J Addict"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1521-0391.2011.00152.x","volume":"20","author":"Brower K.J.","year":"2011","unstructured":"Brower K.J.; Krentzman A.; Robinson E.A.R.; Persistent insomnia, abstinence, and moderate drinking in alcohol-dependent individuals. Am J Addict  2011,20(5),435-440","journal-title":"Am J Addict"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/14656566.2019.1705279","volume":"21","author":"Geoffroy P.A.","year":"2020","unstructured":"Geoffroy P.A.; Lejoyeux M.; Rolland B.; Management of insomnia in alcohol use disorder. Expert Opin Pharmacother  2020,21(3),297-306","journal-title":"Expert Opin Pharmacother"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/add.13772","volume":"112","author":"Dolsen E.A.","year":"2017","unstructured":"Dolsen E.A.; Harvey A.G.; Life-time history of insomnia and hypersomnia symptoms as correlates of alcohol, cocaine and heroin use and relapse among adults seeking substance use treatment in the United States from 1991 to 1994. Addiction  2017,112(6),1104-1111","journal-title":"Addiction"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"107655","DOI":"10.1016\/j.drugalcdep.2019.107655","volume":"206","author":"Kolla B.P.","year":"2020","unstructured":"Kolla B.P.; Mansukhani M.P.; Biernacka J.; Chakravorty S.; Karpyak V.M.; Sleep disturbances in early alcohol recovery: Prevalence and associations with clinical characteristics and severity of alcohol consumption. Drug Alcohol Depend  2020,206,107655","journal-title":"Drug Alcohol Depend"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3389\/fpsyt.2019.00311","volume":"10","author":"Destoop M.","year":"2019","unstructured":"Destoop M.; Morrens M.; Coppens V.; Dom G.; Addiction, anhedonia, and comorbid mood disorder. A narrative review. Front Psychiatry  2019,10,311","journal-title":"Front Psychiatry"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/ijnp\/pyx070","volume":"21","author":"Baune B.T.","year":"2018","unstructured":"Baune B.T.; Brignone M.; Larsen K.G.; A Network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. Int J Neuropsychopharmacol  2018,21(2),97-107","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jad.2017.11.081","volume":"227","author":"Christensen M.C.","year":"2018","unstructured":"Christensen M.C.; Loft H.; McIntyre R.S.; Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders. J Affect Disord  2018,227,787-794","journal-title":"J Affect Disord"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00952990701877078","volume":"34","author":"Martinotti G.","year":"2008","unstructured":"Martinotti G.; Cloninger C.R.; Janiri L.; Temperament and character inventory dimensions and anhedonia in detoxified substance-dependent subjects. Am J Drug Alcohol Abuse  2008,34(2),177-183","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.cobeha.2018.01.024","volume":"22","author":"Cooper J.A.","year":"2018","unstructured":"Cooper J.A.; Arulpragasam A.R.; Treadway M.T.; Anhedonia in depression: biological mechanisms and computational models. Curr Opin Behav Sci  2018,22,128-135","journal-title":"Curr Opin Behav Sci"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.janxdis.2017.08.001","volume":"51","author":"Claycomb Erwin M.","year":"2017","unstructured":"Claycomb Erwin M.; Charak R.; Durham T.A.; Armour C.; Lv X.; Southwick S.M.; Elhai J.D.; Pietrzak R.H.; The 7-factor hybrid model of DSM-5 PTSD symptoms and alcohol consumption and consequences in a national sample of trauma-exposed veterans. J Anxiety Disord  2017,51,14-21","journal-title":"J Anxiety Disord"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1017\/S0033291715000525","volume":"45","author":"Corral-Fr\u00edas N.S.","year":"2015","unstructured":"Corral-Fr\u00edas N.S.; Nikolova Y.S.; Michalski L.J.; Baranger D.A.A.; Hariri A.R.; Bogdan R.; Stress-related anhedonia is associated with ventral striatum reactivity to reward and transdiagnostic psychiatric symptomatology. Psychol Med  2015,45(12),2605-2617","journal-title":"Psychol Med"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/0004867413508455","volume":"48","author":"Garfield J.B.B.","year":"2014","unstructured":"Garfield J.B.B.; Lubman D.I.; Y\u00fccel M.; Anhedonia in substance use disorders: A systematic review of its nature, course and clinical correlates. Aust N Z J Psychiatry  2014,48(1),36-51","journal-title":"Aust N Z J Psychiatry"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1176\/ajp.147.9.1189","volume":"147","author":"Fawcett J.","year":"1990","unstructured":"Fawcett J.; Scheftner W.A.; Fogg L.; Clark D.C.; Young M.A.; Hedeker D.; Gibbons R.; Time-related predictors of suicide in major affective disorder. Am J Psychiatry  1990,147(9),1189-1194","journal-title":"Am J Psychiatry"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1348\/014466508X396549","volume":"48","author":"Morris B.H.","year":"2009","unstructured":"Morris B.H.; Bylsma L.M.; Rottenberg J.; Does emotion predict the course of major depressive disorder? A review of prospective studies. Br J Clin Psychol  2009,48(3),255-273","journal-title":"Br J Clin Psychol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1017\/S0033291711001905","volume":"42","author":"Uher R.","year":"2012","unstructured":"Uher R.; Perlis R.H.; Henigsberg N.; Zobel A.; Rietschel M.; Mors O.; Hauser J.; Dernovsek M.Z.; Souery D.; Bajs M.; Maier W.; Aitchison K.J.; Farmer A.; McGuffin P.; Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med  2012,42(5),967-980","journal-title":"Psychol Med"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.psychres.2014.04.016","volume":"218","author":"Winer E.S.","year":"2014","unstructured":"Winer E.S.; Nadorff M.R.; Ellis T.E.; Allen J.G.; Herrera S.; Salem T.; Anhedonia predicts suicidal ideation in a large psychiatric inpatient sample. Psychiatry Res  2014,218(1-2),124-128","journal-title":"Psychiatry Res"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1192\/bjp.bp.108.051110","volume":"195","author":"Price J.","year":"2009","unstructured":"Price J.; Cole V.; Goodwin G.M.; Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry  2009,195(3),211-217","journal-title":"Br J Psychiatry"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1038\/tp.2014.105","volume":"4","author":"Lally N.","year":"2014","unstructured":"Lally N.; Nugent A.C.; Luckenbaugh D.A.; Ameli R.; Roiser J.P.; Zarate C.A.; Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry  2014,4(10),e469","journal-title":"Transl Psychiatry"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1177\/0269881118793104","volume":"32","author":"Thomas R.K.","year":"2018","unstructured":"Thomas R.K.; Baker G.; Lind J.; Dursun S.; Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness. J Psychopharmacol  2018,32(10),1110-1117","journal-title":"J Psychopharmacol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"115378","DOI":"10.1016\/j.psychres.2023.115378","volume":"327","author":"Pettorruso M.","year":"2023","unstructured":"Pettorruso M.; Guidotti R.; d\u2019Andrea G.; De Risio L.; D\u2019Andrea A.; Chiappini S.; Carullo R.; Barlati S.; Zanardi R.; Rosso G.; De Filippis S.; Di Nicola M.; Andriola I.; Marcatili M.; Nicol\u00f2 G.; Martiadis V.; Bassetti R.; Nucifora D.; De Fazio P.; Rosenblat J.D.; Clerici M.; Maria Dell\u2019Osso B.; Vita A.; Marzetti L.; Sensi S.L.; Di Lorenzo G.; McIntyre R.S.; Martinotti G.; Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING). Psychiatry Res  2023,327,115378","journal-title":"Psychiatry Res"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3390\/brainsci13101494","volume":"13","author":"Pepe M.","year":"2023","unstructured":"Pepe M.; Bartolucci G.; Marcelli I.; Pesaresi F.; Brugnami A.; Caso R.; Fischetti A.; Grisoni F.; Mazza M.; Camardese G.; Di Nicola M.; Sani G.; The patient\u2019s perspective on the effects of intranasal esketamine in treatment-resistant depression. Brain Sci  2023,13(10),1494","journal-title":"Brain Sci"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.euroneuro.2023.04.011","volume":"74","author":"Chiappini S.","year":"2023","unstructured":"Chiappini S.; d\u2019Andrea G.; De Filippis S.; Di Nicola M.; Andriola I.; Bassetti R.; Barlati S.; Pettorruso M.; Sensi S.; Clerici M.; Dell\u2019Osso B.; Vita A.; Martinotti G.; Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study. Eur Neuropsychopharmacol  2023,74,15-21","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","volume":"319","author":"Martinotti G.","year":"2022","unstructured":"Martinotti G.; Vita A.; Fagiolini A.; Maina G.; Bertolino A.; Dell\u2019Osso B.; Siracusano A.; Clerici M.; Bellomo A.; Sani G.; d\u2019Andrea G.; Chiaie R.D.; Conca A.; Barlati S.; Di Lorenzo G.; De Fazio P.; De Filippis S.; Nicol\u00f2 G.; Rosso G.; Valchera A.; Nucifora D.; Di Mauro S.; Bassetti R.; Martiadis V.; Olivola M.; Belletti S.; Andriola I.; Di Nicola M.; Pettorruso M.; McIntyre R.S.; di Giannantonio M.; Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study). J Affect Disord  2022,319,646-654","journal-title":"J Affect Disord"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2147\/NDT.S296451","volume":"17","author":"McIntyre R.S.","year":"2021","unstructured":"McIntyre R.S.; Loft H.; Christensen M.C.; Efficacy of vortioxetine on anhedonia: Results from a pooled analysis of short-term studies in patients with major depressive disorder. Neuropsychiatr Dis Treat  2021,17,575-585","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pnpbp.2019.01.002","volume":"92","author":"Cao B.","year":"2019","unstructured":"Cao B.; Zhu J.; Zuckerman H.; Rosenblat J.D.; Brietzke E.; Pan Z.; Subramanieapillai M.; Park C.; Lee Y.; McIntyre R.S.; Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry  2019,92,109-117","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fpsyt.2019.00017","volume":"10","author":"Cao B.","year":"2019","unstructured":"Cao B.; Park C.; Subramaniapillai M.; Lee Y.; Iacobucci M.; Mansur R.B.; Zuckerman H.; Phan L.; McIntyre R.S.; The efficacy of vortioxetine on anhedonia in patients with major depressive disorder. Front Psychiatry  2019,10,17","journal-title":"Front Psychiatry"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.brs.2018.06.001","volume":"11","author":"Pettorruso M.","year":"2018","unstructured":"Pettorruso M.; Spagnolo P.A.; Leggio L.; Janiri L.; Di Giannantonio M.; Gallimberti L.; Bonci A.; Martinotti G.; Repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex may improve symptoms of anhedonia in individuals with cocaine use disorder: A pilot study. Brain Stimul  2018,11(5),1195-1197","journal-title":"Brain Stimul"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/alcalc\/agq039","volume":"45","author":"Martinotti G.","year":"2010","unstructured":"Martinotti G.; Reina D.; Di Nicola M.; Andreoli S.; Tedeschi D.; Ortolani I.; Pozzi G.; Iannoni E.; D\u2019Iddio S.; Janiri L.; Acetyl-L-carnitine for alcohol craving and relapse prevention in anhedonic alcoholics: a randomized, double-blind, placebo-controlled pilot trial. Alcohol Alcohol  2010,45(5),449-455","journal-title":"Alcohol Alcohol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.pnpbp.2011.01.013","volume":"35","author":"Martinotti G.","year":"2011","unstructured":"Martinotti G.; Andreoli S.; Reina D.; Di Nicola M.; Ortolani I.; Tedeschi D.; Fanella F.; Pozzi G.; Iannoni E.; D\u2019Iddio S.; Prof L.J.; Acetyl-l-Carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects. Prog Neuropsychopharmacol Biol Psychiatry  2011,35(4),953-958","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"401","DOI":"10.9758\/cpn.23.1086","volume":"21","author":"Serretti A.","year":"2023","unstructured":"Serretti A.; Anhedonia and depressive disorders. Clin Psychopharmacol Neurosci  2023,21(3),401-409","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/03007995.2023.2178082","volume":"39","author":"Mattingly G.W.","year":"2023","unstructured":"Mattingly G.W.; Necking O.; Schmidt S.N.; Reines E.; Ren H.; Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies. Curr Med Res Opin  2023,39(4),613-619","journal-title":"Curr Med Res Opin"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/0038038515591947","volume":"51","author":"Sandell K.","year":"2017","unstructured":"Sandell K.; Born\u00e4s H.; Functioning numbness instead of feelings as a direction: young adults\u2019 experiences of antidepressant use. Sociology  2017,51(3),543-558","journal-title":"Sociology"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.addbeh.2007.10.002","volume":"33","author":"Fox H.C.","year":"2008","unstructured":"Fox H.C.; Hong K.A.; Sinha R.; Difficulties in emotion regulation and impulse control in recently abstinent alcoholics compared with social drinkers. Addict Behav  2008,33(2),388-394","journal-title":"Addict Behav"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/nrn3119","volume":"12","author":"Goldstein R.Z.","year":"2011","unstructured":"Goldstein R.Z.; Volkow N.D.; Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci  2011,12(11),652-669","journal-title":"Nat Rev Neurosci"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"e41723","DOI":"10.7554\/eLife.41723","volume":"8","author":"Sawyer K.S.","year":"2019","unstructured":"Sawyer K.S.; Maleki N.; Urban T.; Marinkovic K.; Karson S.; Ruiz S.M.; Harris G.J.; Oscar-Berman M.; Alcoholism gender differences in brain responsivity to emotional stimuli. eLife  2019,8,e41723","journal-title":"eLife"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/npp.2017.283","volume":"43","author":"Yip S.W.","year":"2018","unstructured":"Yip S.W.; Gross J.J.; Chawla M.; Ma S.S.; Shi X.H.; Liu L.; Yao Y.W.; Zhu L.; Worhunsky P.D.; Zhang J.; Is neural processing of negative stimuli altered in addiction independent of drug effects? findings from drug-na\u00efve youth with internet gaming disorder. Neuropsychopharmacology  2018,43(6),1364-1372","journal-title":"Neuropsychopharmacology"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jad.2017.05.048","volume":"221","author":"Goodwin G.M.","year":"2017","unstructured":"Goodwin G.M.; Price J.; De Bodinat C.; Laredo J.; Emotional blunting with antidepressant treatments: A survey among depressed patients. J Affect Disord  2017,221,31-35","journal-title":"J Affect Disord"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.psychres.2014.01.042","volume":"216","author":"Read J.","year":"2014","unstructured":"Read J.; Cartwright C.; Gibson K.; Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants. Psychiatry Res  2014,216(1),67-73","journal-title":"Psychiatry Res"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000080392","volume":"73","author":"Bolling M.Y.","year":"2004","unstructured":"Bolling M.Y.; Kohlenberg R.J.; Reasons for quitting serotonin reuptake inhibitor therapy: paradoxical psychological side effects and patient satisfaction. Psychother Psychosom  2004,73(6),380-385","journal-title":"Psychother Psychosom"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jad.2020.11.106","volume":"283","author":"Fagiolini A.","year":"2021","unstructured":"Fagiolini A.; Florea I.; Loft H.; Christensen M.C.; Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI\/SNRI treatment. J Affect Disord  2021,283,472-479","journal-title":"J Affect Disord"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"291","DOI":"10.31887\/DCNS.2008.10.3\/pgorwood","volume":"10","author":"Gorwood P.","year":"2008","unstructured":"Gorwood P.; Neurobiological mechanisms of anhedonia. Dialogues Clin Neurosci  2008,10(3),291-299","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1146\/annurev-psych-010814-015044","volume":"66","author":"Botvinick M.","year":"2015","unstructured":"Botvinick M.; Braver T.; Motivation and cognitive control: from behavior to neural mechanism. Annu Rev Psychol  2015,66(1),83-113","journal-title":"Annu Rev Psychol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3758\/s13415-014-0300-0","volume":"14","author":"Braver T.S.","year":"2014","unstructured":"Braver T.S.; Krug M.K.; Chiew K.S.; Kool W.; Westbrook J.A.; Clement N.J.; Adcock R.A.; Barch D.M.; Botvinick M.M.; Carver C.S.; Cools R.; Custers R.; Dickinson A.; Dweck C.S.; Fishbach A.; Gollwitzer P.M.; Hess T.M.; Isaacowitz D.M.; Mather M.; Murayama K.; Pessoa L.; Samanez-Larkin G.R.; Somerville L.H.; Mechanisms of motivation-cognition interaction: challenges and opportunities. Cogn Affect Behav Neurosci  2014,14(2),443-472","journal-title":"Cogn Affect Behav Neurosci"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.neubiorev.2019.04.011","volume":"102","author":"Grahek I.","year":"2019","unstructured":"Grahek I.; Shenhav A.; Musslick S.; Krebs R.M.; Koster E.H.W.; Motivation and cognitive control in depression. Neurosci Biobehav Rev  2019,102,371-381","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1017\/S1092852915000747","volume":"21","author":"McIntyre R.S.","year":"2016","unstructured":"McIntyre R.S.; Woldeyohannes H.O.; Soczynska J.K.; Maruschak N.A.; Wium-Andersen I.K.; Vinberg M.; Cha D.S.; Lee Y.; Xiao H.X.; Gallaugher L.A.; Dale R.M.; Alsuwaidan M.T.; Mansur R.B.; Muzina D.J.; Carvalho A.F.; Jerrell J.M.; Kennedy S.H.; Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collab orative Project. CNS Spectr.,  2016,21(5),362-366"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1017\/S1461145714000546","volume":"17","author":"McIntyre R.S.","year":"2014","unstructured":"McIntyre R.S.; Lophaven S.; Olsen C.K.; A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol  2014,17(10),1557-1567","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/da.22063","volume":"30","author":"McIntyre R.S.","year":"2013","unstructured":"McIntyre R.S.; Cha D.S.; Soczynska J.K.; Woldeyohannes H.O.; Gallaugher L.A.; Kudlow P.; Alsuwaidan M.; Baskaran A.; Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety  2013,30(6),515-527","journal-title":"Depress Anxiety"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuropharm.2012.08.001","volume":"64","author":"Goeldner C.","year":"2013","unstructured":"Goeldner C.; Ballard T.M.; Knoflach F.; Wichmann J.; Gatti S.; Umbricht D.; Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Neuropharmacology  2013,64,337-346","journal-title":"Neuropharmacology"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/bs.irn.2020.11.001","volume":"157","author":"Melugin P.R.","year":"2021","unstructured":"Melugin P.R.; Nolan S.O.; Siciliano C.A.; Bidirectional causality between addiction and cognitive deficits. Int Rev Neurobiol  2021,157,371-407","journal-title":"Int Rev Neurobiol"},{"key":"ref=145","year":"2016","unstructured":"Available from:  https:\/\/public4.pagefreezer.com\/browse\/FDA\/04-03-2022T19:30\/ https:\/\/www.fda.gov\/advisory-committees\/psychopharmacologic-drugs-advisory-committee\/2016-meetingmaterials-psychopharmacologic-drugs-advisory-committee2016"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.psychres.2005.11.011","volume":"145","author":"Jaeger J.","year":"2006","unstructured":"Jaeger J.; Berns S.; Uzelac S.; Davis-Conway S.; Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res  2006,145(1),39-48","journal-title":"Psychiatry Res"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2165\/11530230-000000000-00000","volume":"24","author":"Greer T.L.","year":"2010","unstructured":"Greer T.L.; Kurian B.T.; Trivedi M.H.; Defining and measuring functional recovery from depression. CNS Drugs  2010,24(4),267-284","journal-title":"CNS Drugs"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"152113","DOI":"10.1016\/j.comppsych.2019.07.006","volume":"94","author":"Subramaniapillai M.","year":"2019","unstructured":"Subramaniapillai M.; Mansur R.B.; Zuckerman H.; Park C.; Lee Y.; Iacobucci M.; Cao B.; Ho R.; Lin K.; Phan L.; McIntyre R.S.; Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine. Compr Psychiatry  2019,94,152113","journal-title":"Compr Psychiatry"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1080\/03007995.2018.1477746","volume":"34","author":"Chin C.N.","year":"2018","unstructured":"Chin C.N.; Zain A.; Hemrungrojn S.; Ung E.K.; Kwansanit P.; Au Yong K.C.; Chong M.S.W.; Inpa C.; Yen T.H.; Yeoh B.B.D.; Tay L.K.; Bernardo C.; Lim L.C.C.; Yap C.H.; Fones C.; Nayak A.; Nelleman L.; Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA). Curr Med Res Opin  2018,34(11),1975-1984","journal-title":"Curr Med Res Opin"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1017\/S1092852919000786","volume":"24","author":"Chokka P.","year":"2019","unstructured":"Chokka P.; Bougie J.; Proulx J.; Tvistholm A.H.; Ettrup A.; Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study. CNS Spectr  2019,24(6),616-627","journal-title":"CNS Spectr"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","volume":"27","author":"Katona C.","year":"2012","unstructured":"Katona C.; Hansen T.; Olsen C.K.; A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol  2012,27(4),215-223","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2147\/NDT.S358782","volume":"18","author":"Basurte-Villamor I.","year":"2022","unstructured":"Basurte-Villamor I.; Vega P.; Roncero C.; Mart\u00ednez-Raga J.; Grau-L\u00f3pez L.; Aguilar L.; Torrens M.; Szerman N.; Torrens M.; Szerman N.; A feasibility study of patients with major depression and substance use disorders: Vortioxetine as maintenance treatment. Neuropsychiatr Dis Treat  2022,18,965-976","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.chiabu.2003.06.005","volume":"28","author":"Duran B.","year":"2004","unstructured":"Duran B.; Malcoe L.H.; Sanders M.; Waitzkin H.; Skipper B.; Yager J.; Child maltreatment prevalence and mental disorders outcomes among American Indian women in primary care. Child Abuse Negl  2004,28(2),131-145","journal-title":"Child Abuse Negl"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.chiabu.2009.07.001","volume":"34","author":"Tucci A.M.","year":"2010","unstructured":"Tucci A.M.; Kerr-Corr\u00eaa F.; Souza-Formigoni M.L.O.; Childhood trauma in substance use disorder and depression: An analysis by gender among a Brazilian clinical sample. Child Abuse Negl  2010,34(2),95-104","journal-title":"Child Abuse Negl"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s00406-005-0624-4","volume":"256","author":"Anda R.F.","year":"2006","unstructured":"Anda R.F.; Felitti V.J.; Bremner J.D.; Walker J.D.; Whitfield C.; Perry B.D.; Dube S.R.; Giles W.H.; The enduring effects of abuse and related adverse experiences in childhood. Eur Arch Psychiatry Clin Neurosci  2006,256(3),174-186","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0306-4603(01)00204-0","volume":"27","author":"Dube S.R.","year":"2002","unstructured":"Dube S.R.; Anda R.F.; Felitti V.J.; Edwards V.J.; Croft J.B.; Adverse childhood experiences and personal alcohol abuse as an adult. Addict Behav  2002,27(5),713-725","journal-title":"Addict Behav"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1017\/S0033291706008397","volume":"36","author":"Nelson E.C.","year":"2006","unstructured":"Nelson E.C.; Heath A.C.; Lynskey M.T.; Bucholz K.K.; Madden P.A.F.; Statham D.J.; Martin N.G.; Childhood sexual abuse and risks for licit and illicit drug-related outcomes: a twin study. Psychol Med  2006,36(10),1473-1483","journal-title":"Psychol Med"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jad.2003.12.013","volume":"82","author":"Chapman D.P.","year":"2004","unstructured":"Chapman D.P.; Whitfield C.L.; Felitti V.J.; Dube S.R.; Edwards V.J.; Anda R.F.; Adverse childhood experiences and the risk of depressive disorders in adulthood. J Affect Disord  2004,82(2),217-225","journal-title":"J Affect Disord"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2105\/AJPH.91.5.753","volume":"91","author":"Molnar B.E.","year":"2001","unstructured":"Molnar B.E.; Buka S.L.; Kessler R.C.; Child sexual abuse and subsequent psychopathology: results from the National Comorbidity Survey. Am J Public Health  2001,91(5),753-760","journal-title":"Am J Public Health"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1176\/appi.ps.53.8.1001","volume":"53","author":"Anda R.F.","year":"2002","unstructured":"Anda R.F.; Whitfield C.L.; Felitti V.J.; Chapman D.; Edwards V.J.; Dube S.R.; Williamson D.F.; Adverse childhood experiences, alcoholic parents, and later risk of alcoholism and depression. Psychiatr Serv  2002,53(8),1001-1009","journal-title":"Psychiatr Serv"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/archpsyc.64.1.49","volume":"64","author":"Spatz Widom C.","year":"2007","unstructured":"Spatz Widom C.; DuMont K.; Czaja S.J.; A prospective investigation of major depressive disorder and comorbidity in abused and neglected children grown up. Arch Gen Psychiatry  2007,64(1),49-56","journal-title":"Arch Gen Psychiatry"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/sj.npp.1301447","volume":"33","author":"Kippin T.E.","year":"2008","unstructured":"Kippin T.E.; Szumlinski K.K.; Kapasova Z.; Rezner B.; See R.E.; Prenatal stress enhances responsiveness to cocaine. Neuropsychopharmacology  2008,33(4),769-782","journal-title":"Neuropsychopharmacology"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00213-009-1765-3","volume":"214","author":"Van Waes V.","year":"2011","unstructured":"Van Waes V.; Enache M.; Berton O.; Vinner E.; Lhermitte M.; Maccari S.; Darnaud\u00e9ry M.; Effect of prenatal stress on alcohol preference and sensitivity to chronic alcohol exposure in male rats. Psychopharmacology  2011,214(1),197-208","journal-title":"Psychopharmacology"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1523\/JNEUROSCI.4131-13.2014","volume":"34","author":"Marrocco J.","year":"2014","unstructured":"Marrocco J.; Reynaert M.L.; Gatta E.; Gabriel C.; Moca\u00ebr E.; Di Prisco S.; Merega E.; Pittaluga A.; Nicoletti F.; Maccari S.; Morley-Fletcher S.; Mairesse J.; The effects of antidepressant treatment in prenatally stressed rats support the glutamatergic hypothesis of stress-related disorders. J Neurosci  2014,34(6),2015-2024","journal-title":"J Neurosci"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/add.13788","volume":"112","author":"\u00d8stergaard M.L.D.","year":"2017","unstructured":"\u00d8stergaard M.L.D.; Nordentoft M.; Hjorth\u00f8j C.; Associations between substance use disorders and suicide or suicide attempts in people with mental illness: a Danish nation-wide, prospective, register-based study of patients diagnosed with schizophrenia, bipolar disorder, unipolar depression or personal. Addiction  2017,112(7),1250-1259","journal-title":"Addiction"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"106731","DOI":"10.1016\/j.chiabu.2024.106731","volume":"151","author":"Di Nicola M.","year":"2024","unstructured":"Di Nicola M.; Pepe M.; Montanari S.; Marcelli I.; Panaccione I.; Janiri D.; Janiri L.; Sani G.; Childhood sexual abuse and suicide attempts in patients with substance use disorders: The mediating role of emotion dysregulation. Child Abuse Negl  2024,151,106731","journal-title":"Child Abuse Negl"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jad.2015.08.029","volume":"187","author":"Britton P.C.","year":"2015","unstructured":"Britton P.C.; Stephens B.; Wu J.; Kane C.; Gallegos A.; Ashrafioun L.; Tu X.; Conner K.R.; Comorbid depression and alcohol use disorders and prospective risk for suicide attempt in the year following inpatient hospitalization. J Affect Disord  2015,187,151-155","journal-title":"J Affect Disord"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.genhosppsych.2019.12.002","volume":"62","author":"Richards J.E.","year":"2020","unstructured":"Richards J.E.; Shortreed S.M.; Simon G.E.; Penfold R.B.; Glass J.E.; Ziebell R.; Williams E.C.; Ziebell R.; Bradley K.A.; Short-term risk of suicide attempt associated with patterns of patient-reported alcohol use determined by routine AUDIT-C among adults receiving mental healthcare. Gen Hosp Psychiatry  2020,62,79-86","journal-title":"Gen Hosp Psychiatry"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.drugalcdep.2010.08.010","volume":"113","author":"Smith G.W.","year":"2011","unstructured":"Smith G.W.; Farrell M.; Bunting B.P.; Houston J.E.; Shevlin M.; Patterns of polydrug use in Great Britain: Findings from a national household population survey. Drug Alcohol Depend  2011,113(2-3),222-228","journal-title":"Drug Alcohol Depend"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.drugalcdep.2011.10.001","volume":"122","author":"Harrell P.T.","year":"2012","unstructured":"Harrell P.T.; Mancha B.E.; Petras H.; Trenz R.C.; Latimer W.W.; Latent classes of heroin and cocaine users predict unique HIV\/HCV risk factors. Drug Alcohol Depend  2012,122(3),220-227","journal-title":"Drug Alcohol Depend"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fpubh.2013.00061","volume":"1","author":"Quek L.H.","year":"2013","unstructured":"Quek L.H.; Chan G.C.K.; White A.; Connor J.P.; Baker P.J.; Saunders J.B.; Kelly A.B.; Concurrent and simultaneous polydrug use: latent class analysis of an Australian nationally representative sample of young adults. Front Public Health  2013,1,61","journal-title":"Front Public Health"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fpsyt.2013.00079","volume":"4","author":"Connor J.P.","year":"2013","unstructured":"Connor J.P.; Gullo M.J.; Chan G.; Young R.M.; Hall W.D.; Feeney G.F.X.; Polysubstance use in cannabis users referred for treatment: drug use profiles, psychiatric comorbidity and cannabis-related beliefs. Front Psychiatry  2013,4,79","journal-title":"Front Psychiatry"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.drugalcdep.2013.03.004","volume":"132","author":"Trenz R.C.","year":"2013","unstructured":"Trenz R.C.; Scherer M.; Duncan A.; Harrell P.T.; Moleko A.G.; Latimer W.W.; Latent class analysis of polysubstance use, sexual risk behaviors, and infectious disease among South African drug users. Drug Alcohol Depend  2013,132(3),441-448","journal-title":"Drug Alcohol Depend"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/j.addbeh.2013.01.001","volume":"38","author":"White A.","year":"2013","unstructured":"White A.; Chan G.C.K.; Quek L.H.; Connor J.P.; Saunders J.B.; Baker P.; Brackenridge C.; Kelly A.B.; The topography of multiple drug use among adolescent Australians: Findings from the national drug strategy household survey. Addict Behav  2013,38(4),2068-2073","journal-title":"Addict Behav"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.drugalcdep.2009.08.002","volume":"106","author":"Hedden S.L.","year":"2010","unstructured":"Hedden S.L.; Martins S.S.; Malcolm R.J.; Floyd L.; Cavanaugh C.E.; Latimer W.W.; Patterns of illegal drug use among an adult alcohol dependent population: Results from the national survey on drug use and health. Drug Alcohol Depend  2010,106(2-3),119-125","journal-title":"Drug Alcohol Depend"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1097\/MLR.0000000000000731","volume":"55","author":"Bhalla I. P.","year":"2017","unstructured":"Bhalla I. P.; Stefanovics E. A.; Rosenheck R. A.; Clinical epidemiology\nof single versus multiple substance use disorders: Polysubstance\nuse disorder. Med Care  2017,55(Suppl 9 Suppl 2),S24-S32","journal-title":"Med Care"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00952990.2023.2248360","volume":"50","author":"Bunting A.M.","year":"2024","unstructured":"Bunting A.M.; Shearer R.; Linden-Carmichael A.N.; Williams A.R.; Comer S.D.; Cerd\u00e1 M.; Lorvick J.; Are you thinking what I\u2019m thinking? Defining what we mean by \u201cpolysubstance use.\u201d. Am J Drug Alcohol Abuse  2024,50(1),1-7","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1176\/appi.focus.130306","volume":"13","author":"Volkow N.D.","year":"2015","unstructured":"Volkow N.D.; Wang G-J.; Fowler J.S.; Tomasi D.; Addiction circuitry in the human brain. FOCUS  2015,13(3),341-350","journal-title":"FOCUS"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.tins.2021.02.001","volume":"44","author":"Peters K.Z.","year":"2021","unstructured":"Peters K.Z.; Cheer J.F.; Tonini R.; Modulating the neuromodulators: Dopamine, serotonin, and the endocannabinoid system. Trends Neurosci  2021,44(6),464-477","journal-title":"Trends Neurosci"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00213-011-2208-5","volume":"216","author":"Ding Z.M.","year":"2011","unstructured":"Ding Z.M.; Oster S.M.; Hall S.R.; Engleman E.A.; Hauser S.R.; McBride W.J.; Rodd Z.A.; The stimulating effects of ethanol on ventral tegmental area dopamine neurons projecting to the ventral pallidum and medial prefrontal cortex in female Wistar rats: regional difference and involvement of serotonin-3 receptors. Psychopharmacology  2011,216(2),245-255","journal-title":"Psychopharmacology"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0306-4522(01)00593-0","volume":"111","author":"Nocjar C.","year":"2002","unstructured":"Nocjar C.; Roth B.L.; Pehek E.A.; Localization of 5-HT2A receptors on dopamine cells in subnuclei of the midbrain A10 cell group. Neuroscience  2002,111(1),163-176","journal-title":"Neuroscience"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"13367","DOI":"10.1523\/JNEUROSCI.1437-13.2013","volume":"33","author":"Murnane K.S.","year":"2013","unstructured":"Murnane K.S.; Winschel J.; Schmidt K.T.; Stewart L.M.; Rose S.J.; Cheng K.; Rice K.C.; Howell L.L.; Serotonin 2A receptors differentially contribute to abuse-related effects of cocaine and cocaine-induced nigrostriatal and mesolimbic dopamine overflow in nonhuman primates. J Neurosci  2013,33(33),13367-13374","journal-title":"J Neurosci"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1124\/pr.114.009514","volume":"67","author":"Howell L.L.","year":"2015","unstructured":"Howell L.L.; Cunningham K.A.; Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder. Pharmacol Rev  2015,67(1),176-197","journal-title":"Pharmacol Rev"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1523\/JNEUROSCI.5095-09.2010","volume":"30","author":"Gotti C.","year":"2010","unstructured":"Gotti C.; Guiducci S.; Tedesco V.; Corbioli S.; Zanetti L.; Moretti M.; Zanardi A.; Rimondini R.; Mugnaini M.; Clementi F.; Chiamulera C.; Zoli M.; Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. J Neurosci  2010,30(15),5311-5325","journal-title":"J Neurosci"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nrn3110","volume":"12","author":"Heilig M.","year":"2011","unstructured":"Heilig M.; Goldman D.; Berrettini W.; O\u2019Brien C.P.; Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci  2011,12(11),670-684","journal-title":"Nat Rev Neurosci"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41401-019-0299-4","volume":"41","author":"Xiao C.","year":"2020","unstructured":"Xiao C.; Zhou C.; Jiang J.; Yin C.; Neural circuits and nicotinic acetylcholine receptors mediate the cholinergic regulation of midbrain dopaminergic neurons and nicotine dependence. Acta Pharmacol Sin  2020,41(1),1-9","journal-title":"Acta Pharmacol Sin"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0306-4522(00)00241-4","volume":"99","author":"Cheer J.F.","year":"2000","unstructured":"Cheer J.F.; Marsden C.A.; Kendall D.A.; Mason R.; Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study. Neuroscience  2000,99(4),661-667","journal-title":"Neuroscience"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"11070","DOI":"10.1523\/JNEUROSCI.3695-04.2004","volume":"24","author":"Riegel A.C.","year":"2004","unstructured":"Riegel A.C.; Lupica C.R.; Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. J Neurosci  2004,24(49),11070-11078","journal-title":"J Neurosci"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41583-018-0028-x","volume":"19","author":"Darcq E.","year":"2018","unstructured":"Darcq E.; Kieffer B.L.; Opioid receptors: drivers to addiction? Nat Rev Neurosci  2018,19(8),499-514","journal-title":"Nat Rev Neurosci"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.tins.2020.03.011","volume":"43","author":"Lemos Duarte M.","year":"2020","unstructured":"Lemos Duarte M.; Devi L.A.; Post-translational modifications of opioid receptors. Trends Neurosci  2020,43(6),417-432","journal-title":"Trends Neurosci"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/sj.npp.1301438","volume":"33","author":"Walker B.M.","year":"2008","unstructured":"Walker B.M.; Koob G.F.; Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology  2008,33(3),643-652","journal-title":"Neuropsychopharmacology"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"643138","DOI":"10.3389\/fnsyn.2021.643138","volume":"13","author":"Clerke J.","year":"2021","unstructured":"Clerke J.; Preston-Ferrer P.; Zouridis I.S.; Tissot A.; Batti L.; Voigt F.F.; Pag\u00e8s S.; Burgalossi A.; Mameli M.; Output-specific adaptation of habenula-midbrain excitatory synapses during cocaine withdrawal. Front Synaptic Neurosci  2021,13,643138","journal-title":"Front Synaptic Neurosci"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.cell.2015.07.046","volume":"162","author":"Volkow N.D.","year":"2015","unstructured":"Volkow N.D.; Morales M.; The Brain on Drugs: From Reward to Addiction. Cell  2015,162(4),712-725","journal-title":"Cell"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","volume":"3","author":"Koob G.F.","year":"2016","unstructured":"Koob G.F.; Volkow N.D.; Neurobiology of addiction: A neurocircuitry analysis. Lancet Psychiatry  2016,3(8),760-773","journal-title":"Lancet Psychiatry"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nn.2250","volume":"12","author":"Moussawi K.","year":"2009","unstructured":"Moussawi K.; Pacchioni A.; Moran M.; Olive M.F.; Gass J.T.; Lavin A.; Kalivas P.W.; N-Acetylcysteine reverses cocaine-induced metaplasticity. Nat Neurosci  2009,12(2),182-189","journal-title":"Nat Neurosci"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/bs.pbr.2017.07.013","volume":"235","author":"Bobadilla A.C.","year":"2017","unstructured":"Bobadilla A.C.; Heinsbroek J.A.; Gipson C.D.; Griffin W.C.; Fowler C.D.; Kenny P.J.; Kalivas P.W.; Corticostriatal plasticity, neuronal ensembles, and regulation of drug-seeking behavior., Prog Brain Res  2017,235,93-112","journal-title":"Prog Brain Res"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1073\/pnas.0610178104","volume":"104","author":"Ventura R.","year":"2007","unstructured":"Ventura R.; Morrone C.; Puglisi-Allegra S.; Prefrontal\/accumbal catecholamine system determines motivational salience attribution to both reward- and aversion-related stimuli. Proc Natl Acad Sci USA  2007,104(12),5181-5186","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1515\/revneuro-2012-0076","volume":"23","author":"Puglisi-Allegra S.","year":"2012","unstructured":"Puglisi-Allegra S.; Ventura R.; Prefrontal\/accumbal catecholamine system processes emotionally driven attribution of motivational salience. Rev Neurosci  2012,23(5-6),509-526","journal-title":"Rev Neurosci"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fnbeh.2012.00031","volume":"6","author":"Puglisi-Allegra S.","year":"2012","unstructured":"Puglisi-Allegra S.; Ventura R.; Prefrontal\/accumbal catecholamine system processes high motivational salience. Front Behav Neurosci  2012,6,31","journal-title":"Front Behav Neurosci"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1708\/3202.31796","volume":"54","author":"Cuomo A.","year":"2019","unstructured":"Cuomo A.; Ballerini A.; Bruni A.C.; Decina P.; Di Sciascio G.; Fiorentini A.; Scaglione F.; Vampini C.; Fagiolini A.; Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice. Riv Psichiatr  2019,54(4),137-149","journal-title":"Riv Psichiatr"},{"key":"ref=201","unstructured":"European Medicines Agency Brintellix (vortioxetine) Summary\tof Product Characteristics,  Available from: \n https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/brintellix-epar-product-information_en.pdf"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1021\/jm101459g","volume":"54","author":"Bang-Andersen B.","year":"2011","unstructured":"Bang-Andersen B.; Ruhland T.; J\u00f8rgensen M.; Smith G.; Frederiksen K.; Jensen K.G.; Zhong H.; Nielsen S.M.; Hogg S.; M\u00f8rk A.; Stensb\u00f8l T.B.; Discovery of 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem  2011,54(9),3206-3221","journal-title":"J Med Chem"},{"key":"ref=203","first-page":"263","volume":"40","author":"Lovinger D.M.","year":"1991","unstructured":"Lovinger D.M.; White G.; Ethanol potentiation of 5-hydroxytryptamine3 receptor-mediated ion current in neuroblastoma cells and isolated adult mammalian neurons. Mol Pharmacol  1991,40(2),263-270","journal-title":"Mol Pharmacol"},{"key":"ref=204","unstructured":"European Medicines Agency Spravato  (esketamine) Summary\tof Product Characteristics,   Available from:    https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spravato-epar-product-information_en.pdf"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/mp.2017.255","volume":"23","author":"Zanos P.","year":"2018","unstructured":"Zanos P.; Gould T.D.; Mechanisms of ketamine action as an antidepressant. Mol Psychiatry  2018,23(4),801-811","journal-title":"Mol Psychiatry"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3389\/fpsyt.2016.00047","volume":"7","author":"Zhang M.W.B.","year":"2016","unstructured":"Zhang M.W.B.; Ho R.C.M.; Controversies of the effect of ketamine on cognition. Front Psychiatry  2016,7,47","journal-title":"Front Psychiatry"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"e0173202","DOI":"10.1371\/journal.pone.0173202","volume":"12","author":"Zhang M.W.B.","year":"2017","unstructured":"Zhang M.W.B.; Hong Y.X.; Husain S.F.; Harris K.M.; Ho R.C.M.; Analysis of print news media framing of ketamine treatment in the United States and Canada from 2000 to 2015. PLoS One  2017,12(3),e0173202","journal-title":"PLoS One"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1097\/00004583-200210000-00016","volume":"41","author":"Riggs P.D.","year":"2002","unstructured":"Riggs P.D.; Davies R.D.; A clinical approach to integrating treatment for adolescent depression and substance abuse. J Am Acad Child Adolesc Psychiatry  2002,41(10),1253-1255","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1080\/19371918.2013.774673","volume":"28","author":"Kelly T.M.","year":"2013","unstructured":"Kelly T.M.; Daley D.C.; Integrated treatment of substance use and psychiatric disorders. Soc Work Public Health  2013,28(3-4),388-406","journal-title":"Soc Work Public Health"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1089\/cap.2005.15.777","volume":"15","author":"Solhkhah R.","year":"2005","unstructured":"Solhkhah R.; Wilens T.E.; Daly J.; Prince J.B.; Patten S.L.V.; Biederman J.; Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit\/hyperactivity disorder and mood disorders. J Child Adolesc Psychopharmacol  2005,15(5),777-786","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2004.09.004","volume":"78","author":"Torrens M.","year":"2005","unstructured":"Torrens M.; Fonseca F.; Mateu G.; Farr\u00e9 M.; Efficacy of antidepressants in substance use disorders with and without comorbid depression. Drug Alcohol Depend  2005,78(1),1-22","journal-title":"Drug Alcohol Depend"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"128","DOI":"10.20882\/adicciones.1559","volume":"34","author":"Torrens M.","year":"2022","unstructured":"Torrens M.; Tirado-Mu\u00f1oz J.; Fonseca F.; Farr\u00e9 M.; Gonz\u00e1lez-Pinto A.; Arrojo M.; Bernardo M.; Arranz B.; Garriga M.; S\u00e1iz P.A.; Fl\u00f3rez G.; Goikolea J.M.; Zorrilla I.; Cunill R.; Castells X.; Beco\u00f1a E.; L\u00f3pez A.; San L.; Clinical practice guideline on pharmacological and psychological management of adult patients with depression and a comorbid substance use disorder. Adicciones  2022,34(2),128-141","journal-title":"Adicciones"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"CD002950","DOI":"10.1002\/14651858.CD002950.pub3","volume":"CD002950","author":"Pani P.P.","year":"2011","unstructured":"Pani P.P.; Trogu E.; Vecchi S.; Amato L.; Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Libr  2011,CD002950(12),CD002950","journal-title":"Cochrane Libr"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/add.12698","volume":"110","author":"Zhou X.","year":"2015","unstructured":"Zhou X.; Qin B.; Del Giovane C.; Pan J.; Gentile S.; Liu Y.; Lan X.; Yu J.; Xie P.; Efficacy and tolerability of antidepressants in the treatment of adolescents and young adults with depression and substance use disorders: a systematic review and meta-analysis. Addiction  2015,110(1),38-48","journal-title":"Addiction"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.addbeh.2005.07.007","volume":"30","author":"Cornelius J.R.","year":"2005","unstructured":"Cornelius J.R.; Clark D.B.; Bukstein O.G.; Birmaher B.; Salloum I.M.; Brown S.A.; Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: A review. Addict Behav  2005,30(9),1824-1833","journal-title":"Addict Behav"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"e27632","DOI":"10.7759\/cureus.27632","volume":"14","author":"Sato T.","year":"2022","unstructured":"Sato T.; Interventions for co-occurring cannabis use and depression. Cureus  2022,14(8),e27632","journal-title":"Cureus"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1874473707666141015220608","volume":"7","author":"Deady M.","year":"2014","unstructured":"Deady M.; Teesson M.; Kay-Lambkin F.; Treatments for co-occurring depression and substance use in young people: a systematic review. Curr Drug Abuse Rev  2014,7(1),3-17","journal-title":"Curr Drug Abuse Rev"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/YCO.0000000000000510","volume":"32","author":"Murthy P.","year":"2019","unstructured":"Murthy P.; Mahadevan J.; Chand P.K.; Treatment of substance use disorders with co-occurring severe mental health disorders. Curr Opin Psychiatry  2019,32(4),293-299","journal-title":"Curr Opin Psychiatry"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/ajad.12581","volume":"26","author":"Hassan A.N.","year":"2017","unstructured":"Hassan A.N.; Howe A.S.; Samokhvalov A.V.; Le Foll B.; George T.P.; George T.P.; Zawertailo L.; Management of mood and anxiety disorders in patients receiving opioid agonist therapy: Review and meta-analysis. Am J Addict  2017,26(6),551-563","journal-title":"Am J Addict"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00228-022-03303-4","volume":"78","author":"Fluyau D.","year":"2022","unstructured":"Fluyau D.; Mitra P.; Jain A.; Kailasam V.K.; Pierre C.G.; Selective serotonin reuptake inhibitors in the treatment of depression, anxiety, and post-traumatic stress disorder in substance use disorders: a Bayesian meta-analysis. Eur J Clin Pharmacol  2022,78(6),931-942","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1300\/J069v13n03_02","volume":"13","author":"Nunes E.V.","year":"1995","unstructured":"Nunes E.V.; Quitkin F.; Brady R.; Post-Koenig T.; Antidepressant treatment in methadone maintenance patients. J Addict Dis  1995,13(3),13-24","journal-title":"J Addict Dis"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.biopsych.2004.06.037","volume":"56","author":"Nunes E.V.","year":"2004","unstructured":"Nunes E.V.; Sullivan M.A.; Levin F.R.; Treatment of depression in patients with opiate dependence. Biol Psychiatry  2004,56(10),793-802","journal-title":"Biol Psychiatry"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/JCP.0b013e31822c0adf","volume":"31","author":"Pedrelli P.","year":"2011","unstructured":"Pedrelli P.; Iovieno N.; Vitali M.; Tedeschini E.; Bentley K.H.; Papakostas G.I.; Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis. J Clin Psychopharmacol  2011,31(5),582-586","journal-title":"J Clin Psychopharmacol"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"CD008373","DOI":"10.1002\/14651858.CD008373.pub2","volume":"CD008373","author":"Pani P.P.","year":"2010","unstructured":"Pani P.P.; Vacca R.; Trogu E.; Amato L.; Davoli M.; Pharmacological treatment for depression during opioid agonist treatment for opioid dependence. Cochrane Libr  2010,CD008373(9),CD008373","journal-title":"Cochrane Libr"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jsat.2010.05.014","volume":"39","author":"Stein M.D.","year":"2010","unstructured":"Stein M.D.; Herman D.S.; Kettavong M.; Cioe P.A.; Friedmann P.D.; Tellioglu T.; Anderson B.J.; Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. J Subst Abuse Treat  2010,39(2),157-166","journal-title":"J Subst Abuse Treat"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"21m14001","DOI":"10.4088\/JCP.21m14001","volume":"83","author":"Zhang K.","year":"2022","unstructured":"Zhang K.; Jones C. M.; Compton W. M.; Guy G. P.; Evans M. E.; Volkow N. D.;  Association between receipt of antidepressants\nand retention in buprenorphine treatment for opioid use disorder: A\npopulation-based retrospective cohort study. J Clin Psychiatry,  2022,83(3),21m14001","journal-title":"J Clin Psychiatry,"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"10254","DOI":"10.3389\/adar.2022.10254","volume":"2","author":"Namchuk A.B.","year":"2022","unstructured":"Namchuk A.B.; Lucki I.; Browne C.A.; Buprenorphine as a treatment for major depression and opioid use disorder. Advances in Drug and Alcohol Research  2022,2,10254","journal-title":"Advances in Drug and Alcohol Research"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1192\/pb.bp.110.031831","volume":"35","author":"Petry N.M.","year":"2011","unstructured":"Petry N.M.; Contingency management: what it is and why psychiatrists should want to use it. Psychiatrist  2011,35(5),161-163","journal-title":"Psychiatrist"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/15504263.2014.924772","volume":"10","author":"Kelly T.M.","year":"2014","unstructured":"Kelly T.M.; Daley D.C.; Douaihy A.B.; Contingency management for patients with dual disorders in intensive outpatient treatment for addiction. J Dual Diagn  2014,10(3),108-117","journal-title":"J Dual Diagn"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/00952990701301319","volume":"33","author":"Carroll K.M.","year":"2007","unstructured":"Carroll K.M.; Rounsaville B.J.; A perfect platform: combining contingency management with medications for drug abuse. Am J Drug Alcohol Abuse  2007,33(3),343-365","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0376-8716(03)00032-2","volume":"70","author":"Kosten T.","year":"2003","unstructured":"Kosten T.; Oliveto A.; Feingold A.; Poling J.; Sevarino K.; McCance-Katz E.; Stine S.; Gonzalez G.; Gonsai K.; Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend  2003,70(3),315-325","journal-title":"Drug Alcohol Depend"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1001\/archpsyc.63.2.219","volume":"63","author":"Poling J.","year":"2006","unstructured":"Poling J.; Oliveto A.; Petry N.; Sofuoglu M.; Gonsai K.; Gonzalez G.; Martell B.; Kosten T.R.; Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry  2006,63(2),219-228","journal-title":"Arch Gen Psychiatry"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.neubiorev.2021.05.006","volume":"126","author":"Worrell S.D.","year":"2021","unstructured":"Worrell S.D.; Gould T.J.; Therapeutic potential of ketamine for alcohol use disorder. Neurosci Biobehav Rev  2021,126,573-589","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/978-981-33-6044-0_22","volume":"Vol. 1305","author":"Fornaro M.","year":"2021","unstructured":"Fornaro M.; De Berardis D.; Anastasia A.; Fusco A.;  In: Adv Exp Med Biol  2021,Vol. 1305,449-461","journal-title":"In: Adv Exp Med Biol"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","volume":"76","author":"Yoon G.","year":"2019","unstructured":"Yoon G.; Petrakis I.L.; Krystal J.H.; Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA Psychiatry  2019,76(3),337-338","journal-title":"JAMA Psychiatry"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1590\/1516-4446-2019-0690","volume":"42","author":"De Berardis D.","year":"2020","unstructured":"De Berardis D.; Fornaro M.; Anastasia A.; Vellante F.; Olivieri L.; Rapini G.; Serroni N.; Orsolini L.; Valchera A.; Carano A.; Tomasetti C.; Ventriglio A.; Bustini M.; Pompili M.; Serafini G.; Perna G.; Iasevoli F.; Martinotti G.; Di Giannantonio M.; Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a \u201creal-world\u201d chart review study. Br J Psychiatry  2020,42(3),317-321","journal-title":"Br J Psychiatry"},{"key":"ref=237","doi-asserted-by":"publisher","first-page":"e2750","DOI":"10.1002\/hup.2750","volume":"35","author":"De Carlo V.","year":"2020","unstructured":"De Carlo V.; Vismara M.; Grancini B.; Benatti B.; Bosi M.F.; Colombo A.; Vigan\u00f2 C.A.; Dell\u2019Osso B.; Mazza M.G.; Effectiveness, tolerability, and dropout rates of vortioxetine in comorbid depression: A naturalistic study. Hum Psychopharmacol  2020,35(5),e2750","journal-title":"Hum Psychopharmacol"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/ADM.0000000000000575","volume":"14","author":"Pettorruso M.","year":"2020","unstructured":"Pettorruso M.; di Giannantonio M.; De Risio L.; Martinotti G.; Koob G.F.; A light in the darkness: Repetitive transcranial magnetic stimulation (rTMS) to treat the hedonic dysregulation of addiction. J Addict Med  2020,14(4),272-274","journal-title":"J Addict Med"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"110513","DOI":"10.1016\/j.pnpbp.2022.110513","volume":"116","author":"Martinotti G.","year":"2022","unstructured":"Martinotti G.; Pettorruso M.; Montemitro C.; Spagnolo P.A.; Acuti Martellucci C.; Di Carlo F.; Fanella F.; di Giannantonio M.; Repetitive transcranial magnetic stimulation in treatment-seeking subjects with cocaine use disorder: A randomized, double-blind, sham-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry  2022,116,110513","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=240","year":"2011","unstructured":"National Institute for Health and Care Excellence (NICE)  National\nCollaborating Centre for Mental Health (Great Britain), National\nInstitute for Health, and Clinical Excellence (Great Britain). Alcohol\nuse disorders: The NICE guideline on the diagnosis, assessment\nand management of harmful drinking and alcohol dependence,  Available from:  https:\/\/www.nice.org.uk\/guidance\/cg1152011"},{"key":"ref=241","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.4088\/JCP.10m06217","volume":"72","author":"Iovieno N.","year":"2011","unstructured":"Iovieno N.; Tedeschini E.; Bentley K.H.; Evins A.E.; Papakostas G.I.; Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry  2011,72(8),1144-1151","journal-title":"J Clin Psychiatry"},{"key":"ref=242","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/00325481.2017.1249265","volume":"129","author":"Khouzam H.R.","year":"2017","unstructured":"Khouzam H.R.; A review of trazodone use in psychiatric and medical conditions. Postgrad Med  2017,129(1),140-148","journal-title":"Postgrad Med"},{"key":"ref=243","doi-asserted-by":"publisher","first-page":"CD008581","DOI":"10.1002\/14651858.CD008581.pub2","volume":"4","author":"Agabio R.","year":"2018","unstructured":"Agabio R.; Trogu E.; Pani P.P.; Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. Cochrane Database Syst Rev  2018,4,CD008581","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=244","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/14656566.2018.1561870","volume":"20","author":"Hillemacher T.","year":"2019","unstructured":"Hillemacher T.; Frieling H.; Pharmacotherapeutic options for co-morbid depression and alcohol dependence. Expert Opin Pharmacother  2019,20(5),547-569","journal-title":"Expert Opin Pharmacother"},{"key":"ref=245","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1177\/0706743720915420","volume":"65","author":"Stokes P.R.A.","year":"2020","unstructured":"Stokes P.R.A.; Jokinen T.; Amawi S.; Qureshi M.; Husain M.I.; Yatham L.N.; Strang J.; Young A.H.; Voon V.; Nutt D.J.; Erritzoe D.; Howes O.; Leech R.; Mehta M.; Selvaraj S.; Young A.H.; Newhouse S.; Grasby P.; Sagnay de la Bastida V.; Merlo Pich E.; Murphy A.L.; Morrison P.D.; Pharmacological treatment of mood disorders and comorbid addictions: a systematic review and meta-analysis: Traitement pharmacologique des troubles de l\u2019humeur et des d\u00e9pendances comorbides: une revue syst\u00e9matique et une m\u00e9ta-analyse. Can J Psychiatry  2020,65(11),749-769","journal-title":"Can J Psychiatry"},{"key":"ref=246","doi-asserted-by":"publisher","first-page":"e1003822","DOI":"10.1371\/journal.pmed.1003822","volume":"18","author":"Grant S.","year":"2021","unstructured":"Grant S.; Azhar G.; Han E.; Booth M.; Motala A.; Larkin J.; Hempel S.; Dass N.; Sajjad R.; Rajput K.; Clinical interventions for adults with comorbid alcohol use and depressive disorders: A systematic review and network meta-analysis. PLoS Med  2021,18(10),e1003822","journal-title":"PLoS Med"},{"key":"ref=247","year":"2021","unstructured":"US Department of Veterans Affairs US Department of Defense VA\/DoD Clinical Practice Guideline for the Management of Substance use Disorders.  Available from:  https:\/\/www.healthquality.va.gov\/guidelines\/MH\/sud\/VADoDSUDCPG.pdf2021"},{"key":"ref=248","doi-asserted-by":"publisher","first-page":"57","DOI":"10.17116\/jnevro202112112157","volume":"121","author":"Vinnikova M.A.","year":"2021","unstructured":"Vinnikova M.A.; Severtsev V.V.; Komarov S.D.; Vdovin A.S.; Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study. Zh Nevrol Psikhiatr Im S S Korsakova  2021,121(12),57-62","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref=249","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1097\/MJT.0000000000001388","volume":"29","author":"Zastrozhin M.","year":"2022","unstructured":"Zastrozhin M.; Skryabin V.; Smirnov V.; Zastrozhina A.; Grishina E.; Ryzhikova K.; Bure I.; Golovinskii P.; Koporov S.; Bryun E.; Sychev D.; Effect of genetic polymorphism of the CYP2D6 gene on the efficacy and safety of fluvoxamine in major depressive disorder. Am J Ther  2022,29(1),e26-e33","journal-title":"Am J Ther"},{"key":"ref=250","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41397-021-00219-7","volume":"21","author":"Zastrozhin M.S.","year":"2021","unstructured":"Zastrozhin M.S.; Skryabin V.Y.; Petukhov A.E.; Torrado M.V.; Pankratenko E.P.; Zastrozhina A.K.; Grishina E.A.; Ryzhikova K.A.; Shipitsyn V.V.; Bryun E.A.; Sychev D.A.; Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder. Pharmacogenomics J  2021,21(4),435-439","journal-title":"Pharmacogenomics J"},{"key":"ref=251","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/PRA.0000000000000568","volume":"27","author":"Zastrozhin M.S.","year":"2021","unstructured":"Zastrozhin M.S.; Skryabin V.Y.; Petukhov A.E.; Pankratenko E.P.; Grishina E.A.; Ryzhikova K.A.; Torrado M.V.; Shipitsyn V.V.; Bryun E.A.; Sychev D.A.; Impact of CYP2D6 polymorphism on equilibrium concentration of fluoxetine in patients diagnosed with major depressive disorder and comorbid alcohol use disorders. J Psychiatr Pract  2021,27(5),372-379","journal-title":"J Psychiatr Pract"},{"key":"ref=252","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1021\/jm301783x","volume":"56","author":"Carroll F.I.","year":"2013","unstructured":"Carroll F.I.; Carlezon W.A.; Development of \u03ba opioid receptor antagonists. J Med Chem  2013,56(6),2178-2195","journal-title":"J Med Chem"},{"key":"ref=253","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.alcohol.2011.10.006","volume":"46","author":"Walker B.M.","year":"2012","unstructured":"Walker B.M.; Valdez G.R.; McLaughlin J.P.; Bakalkin G.; Targeting dynorphin\/kappa opioid receptor systems to treat alcohol abuse and dependence. Alcohol  2012,46(4),359-370","journal-title":"Alcohol"},{"key":"ref=254","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41591-020-0806-7","volume":"26","author":"Krystal A.D.","year":"2020","unstructured":"Krystal A.D.; Pizzagalli D.A.; Smoski M.; Mathew S.J.; Nurnberger J.; Lisanby S.H.; Iosifescu D.; Murrough J.W.; Yang H.; Weiner R.D.; Calabrese J.R.; Sanacora G.; Hermes G.; Keefe R.S.E.; Song A.; Goodman W.; Szabo S.T.; Whitton A.E.; Gao K.; Potter W.Z.; A randomized proof-of-mechanism trial applying the \u2018fast-fail\u2019 approach to evaluating \u03ba-opioid antagonism as a treatment for anhedonia. Nat Med  2020,26(5),760-768","journal-title":"Nat Med"},{"key":"ref=255","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1176\/appi.ps.56.8.913","volume":"56","author":"Watkins K.E.","year":"2005","unstructured":"Watkins K.E.; Hunter S.B.; Burnam M.A.; Pincus H.A.; Nicholson G.; Leda L.S.; Review of treatment recommendations for persons with a co-occurring affective or anxiety and substance use disorder. Psychiatr Serv  2005,56(8),913-926","journal-title":"Psychiatr Serv"},{"key":"ref=256","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1176\/appi.ajp.2019.19121284","volume":"177","author":"Volkow N.D.","year":"2020","unstructured":"Volkow N.D.; Personalizing the treatment of substance use disorders. Am J Psychiatry  2020,177(2),113-116","journal-title":"Am J Psychiatry"},{"key":"ref=257","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1017\/S1092852915000826","volume":"20","author":"McIntyre R.S.","year":"2015","unstructured":"McIntyre R.S.; Lee Y.; Mansur R.B.; Treating to target in major depressive disorder: response to remission to functional recovery. CNS Spectr  2015,20(S1),17-31","journal-title":"CNS Spectr"},{"key":"ref=258","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1017\/S1461145702002870","volume":"5","author":"Opbroek A.","year":"2002","unstructured":"Opbroek A.; Delgado P.L.; Laukes C.; McGahuey C.; Katsanis J.; Moreno F.A.; Manber R.; Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol  2002,5(2),147-151","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=259","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.euroneuro.2012.04.006","volume":"23","author":"Pehrson A.L.","year":"2013","unstructured":"Pehrson A.L.; Cremers T.; B\u00e9try C.; van der Hart M.G.C.; J\u00f8rgensen L.; Madsen M.; Haddjeri N.; Ebert B.; Sanchez C.; Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-A rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol  2013,23(2),133-145","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=260","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40262-016-0389-0","volume":"55","author":"Chen G.","year":"2016","unstructured":"Chen G.; Nomikos G.G.; Affinito J.; Zhao Z.; Lack of effect of vortioxetine on the pharmacokinetics and pharmacodynamics of ethanol, diazepam, and lithium. Clin Pharmacokinet  2016,55(9),1115-1127","journal-title":"Clin Pharmacokinet"},{"key":"ref=261","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/1871527315666161025140111","volume":"16","author":"Orsolini L.","year":"2017","unstructured":"Orsolini L.; Tomasetti C.; Valchera A.; Iasevoli F.; Buonaguro E.F.; Fornaro M.; Fiengo A.L.C.; Martinotti G.; Vellante F.; Matarazzo I.; Vecchiotti R.; Perna G.; Di Nicola M.; Carano A.; Di Bartolomeis A.; De Giannantonio M.; De Berardis D.; Current and future perspectives on the major depressive disorder: Focus on the new multimodal antidepressant vortioxetine. CNS Neurol Disord Drug Targets  2017,16(1),65-92","journal-title":"CNS Neurol Disord Drug Targets"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X22666240827165327","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/233425\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X22666240827165327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T09:13:38Z","timestamp":1737018818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/233425\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":261,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x22666240827165327","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-01-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}